Baxter, Kuros sign product license, collaboration agreement

By Jennifer Chiou

New York, Nov. 17 - Subsidiaries of Baxter International Inc. and Kuros Biosurgery AG announced they signed an agreement under which Kuros has granted Baxter exclusive worldwide rights to develop and market a portfolio of hard and soft tissue-repair products.

The products will be based on Baxter's fibrin-based biomatrix, Tisseel fibrin sealant, combined with Kuros' biologics and binding technology, the companies said.

Baxter's Tisseel combined with Kuros' biologics and fibrin-based binding technology enable growth factors to be attached to fibrin, enhancing the regeneration of bone and soft tissue.

"This agreement positions our BioSurgery business to enter the fast-growing orthobiologic market," Baxter BioScience president Joy Amundson said in a news release.

"In addition, the products developed under this agreement complement our current product portfolio and build on our strategy to develop surgical therapies for tissue and bone regeneration."

Under the agreement, Kuros will receive upfront and milestone payments, as well as royalties on global product sales. The companies will continue to collaborate through phase 2 clinical trials, and Baxter will manage phase 3 clinical development and regulatory licensing.

No other terms of the agreement were disclosed.

Deerfield, Ill.-based Baxter Healthcare Corp. is the principal U.S. operating subsidiary of Baxter International. It assists health care professionals with treatment of medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma.

Kuros is a Zurich, Switzerland, biomedical company focused on injectable biologics to repair and regenerate injured or diseased tissues.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.